Fig. (1).
Oxaliplatin pathways: thin dotted arrows indicate pathways that are not deemed relevant in oxaliplatin DDR compared with cisplatin (this diagram has been reproduced with modifications from http://www.pharmgkb.org. Permission has been given by PharmGKB and Stanford University; copyright PharmGKB).